Emergent Signs a Five-Year Manufacturing Services Agreement with Janssen for Ad26.COV2-S to Treat COVID-19
Shots:
- Emergent will be responsible to provide large-scale drug substance for manufacturing Janssen’s Ad26.COV2-S for the first two years valued at ~$480M in 2021. Additionally- at the beginning of 2023 Emergent will provide capacity deployment model for supporting additional drug substance batches annually for three years
- The manufacturing practices will be performed at Emergent’s Baltimore Bayview facility a designated Center for Innovation in Advanced Development and Manufacturing (CIADM) by the US Department of HHS targeted for developing large quantities of vaccines and treatments
- Emergent’s facility has four independent suites to produce at clinical scale and move to the clinic also allows scaling up of large-scale manufacturing to up to 4000L. Additionally- it holds the capacity to produce millions of doses of vaccines annually
Click here to read full press release/ article
Ref: Emergent | Image: Janssen
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com